Sermorelin
| Clinical data | |
|---|---|
| Trade names | Geref |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Pregnancy category |
|
| Routes of administration | Injection |
| ATC code | H01AC04 (WHO) V04CD03 (WHO) |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| Synonyms | GRF 1–29 |
| CAS Number |
86168-78-7 |
| PubChem (CID) | 16132413 |
| DrugBank |
DB00010 |
| ChemSpider |
17289071 |
| UNII |
89243S03TE |
| KEGG |
D08509 |
| ChEMBL |
CHEMBL1201490 |
| Chemical and physical data | |
| Formula | C149H246N44O42S |
| Molar mass | 3357.882 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
| | |
Sermorelin (INN) (trade name is Geref), also known as GHRH (1-29), is a growth hormone-releasing hormone (GHRH) analogue used as a diagnostic agent. It is a 29-amino acid polypeptide representing the 1–29 fragment from endogenous human GHRH, and is thought to be the shortest fully functional fragment of GHRH.[1] It is used as a diagnostic agent to assess growth hormone (GH) secretion.[2]
See also
References
- ↑ Prakash A, Goa KL (August 1999). "Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency". BioDrugs. 12 (2): 139–57. doi:10.2165/00063030-199912020-00007. PMID 18031173.
- ↑ Pharmacology (Rang, Dale, Ritter & Moore, ISBN 0-443-07145-4, 5th ed., Churchill Livingstone 2003).
This article is issued from Wikipedia - version of the 8/18/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.